racotumomab

Ligand id: 7995

Name: racotumomab

References
1. Alfonso M, Díaz A, Hernández AM, Pérez A, Rodríguez E, Bitton R, Pérez R, Vázquez AM. (2002)
An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients.
J. Immunol.168 (5): 2523-9. [PMID:11859147]
2. Grant SC, Kris MG, Houghton AN, Chapman PB. (1999)
Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin.
Clin. Cancer Res.5 (6): 1319-23. [PMID:10389914]
3. Hayashi N, Chiba H, Kuronuma K, Go S, Hasegawa Y, Takahashi M, Gasa S, Watanabe A, Hasegawa T, Kuroki Y et al.. (2013)
Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody.
Cancer Sci.104 (1): 43-7. [PMID:23004020]
4. Inoue S, Sato C, Kitajima K. (2010)
Extensive enrichment of N-glycolylneuraminic acid in extracellular sialoglycoproteins abundantly synthesized and secreted by human cancer cells.
Glycobiology20 (6): 752-62. [PMID:20197272]
5. Malykh YN, Schauer R, Shaw L. (2001)
N-Glycolylneuraminic acid in human tumours.
Biochimie83 (7): 623-34. [PMID:11522391]
6. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, Perez R, Ando S. (1996)
Gangliosides expressed in human breast cancer.
Cancer Res.56 (22): 5165-71. [PMID:8912852]
7. McCaffery M, Yao TJ, Williams L, Livingston PO, Houghton AN, Chapman PB. (1996)
Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.
Clin. Cancer Res.2 (4): 679-86. [PMID:9816218]
8. Nakarai H, Chandler PJ, Kano K, Morton DL, Irie RF. (1990)
Hanganutziu-Deicher antigen as a possible target for immunotherapy of melanoma.
Int. Arch. Allergy Appl. Immunol.91 (3): 323-8. [PMID:2354874]
9. Nakarai H, Saida T, Shibata Y, Irie RF, Kano K. (1987)
Expression of heterophile, Paul-Bunnell and Hanganutziu-Deicher antigens on human melanoma cell lines.
Int. Arch. Allergy Appl. Immunol.83 (2): 160-6. [PMID:3294601]
10. Scursoni AM, Galluzzo L, Camarero S, Lopez J, Lubieniecki F, Sampor C, Segatori VI, Gabri MR, Alonso DF, Chantada G et al.. (2011)
Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer.
Clin. Dev. Immunol.2011: 245181. [PMID:21941577]
11. van Cruijsen H, Ruiz MG, van der Valk P, de Gruijl TD, Giaccone G. (2009)
Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer.
BMC Cancer9: 180. [PMID:19519895]
12. Yao TJ, Meyers M, Livingston PO, Houghton AN, Chapman PB. (1999)
Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.
Clin. Cancer Res.5 (1): 77-81. [PMID:9918205]